Zimmer Holdings Inc. (NYSE:ZMH-WI) today announced the election of new members to its board of directors and the designation of Ray Elliott as chairman of the board of directors and chief executive officer. These actions complete the establishment of an initial five-person board in connection with the distribution today of all of the outstanding shares of Zimmer Holdings to the holders of Bristol-Myers Squibb Co. (NYSE:BMY) common stock.

Joining Elliott on the board are: Larry C. Glasscock, president and chief executive officer of Anthem Insurance Companies; Regina E. Herzlinger, professor of business administration, Harvard Business School; John L. McGoldrick, executive vice president, Bristol-Myers Squibb Co.; and Augustus A. White III, M.D., professor of orthopedic surgery, Harvard Medical School. Elliott was elected a director on March 20.

"In Larry, Regi, John and Gus we have four outstanding leaders who will contribute greatly based on the experiences and expertise they bring to the board," said Elliott, who has served as Zimmer Holdings' president and CEO since March, and president of Zimmer Inc. since 1997.

Zimmer, based in Warsaw, is a global leader in the design, development, manufacturing and marketing of orthopedic reconstructive implants and fracture management products. Orthopedic reconstructive implants restore joint function lost due to disease or trauma in knees, hips, shoulders and elbows.

Fracture management products are devices used primarily to reattach or stabilize damaged bone and tissue to support the body's natural healing process. Zimmer also manufactures and markets other products related to orthopedic and general surgery.

Zimmer was founded in 1927 and has more than 3,200 employees worldwide. For 2000, Zimmer recorded worldwide revenues of more than $1 billion. For further information regarding Zimmer and its spin-off from Bristol-Myers Squibb Co., please see Zimmer's Form 10, which is filed with the Securities and Exchange Commission. [[In-content Ad]]